Keyphrases
Pancreatic Duct Cells
100%
Phosphoinositide 3-kinase (PI3K)
100%
Pancreatic Cancer Cells
100%
P27Kip1
100%
MTOR Inhibitor
100%
BEZ235
83%
Pancreatic Ductal Adenocarcinoma
50%
KRAS G12C
50%
Clinical Trials
33%
Adenocarcinoma Cells
33%
Therapeutic Intervention
16%
Haploinsufficiency
16%
Cancer Development
16%
Dose Effect
16%
Targeted Therapeutics
16%
Extracellular Matrix Protein 1 (ECM1)
16%
Targeted Therapy
16%
Poor Prognosis
16%
Tumor Model
16%
MTOR Pathway
16%
Cell Sensitivity
16%
Gene Dosage
16%
Cyclin-dependent Kinase Inhibitor
16%
Unbiased Approach
16%
Phosphatidylinositol 3-kinase Inhibitor
16%
Control Sensitivity
16%
Signaling Nodes
16%
Medicine and Dentistry
Pancreas Adenocarcinoma
100%
Cancer Cell
100%
Pancreas Cancer
100%
Mammalian Target of Rapamycin Inhibitor
100%
Phosphoinositide 3-Kinase
100%
BEZ235
55%
Clinical Trial
22%
Adenocarcinoma Cell Line
22%
Malignant Neoplasm
11%
Haploinsufficiency
11%
Targeted Therapy
11%
Tumor Model
11%
Cyclin Dependent Kinase Inhibitor
11%
Phosphoinositide 3-Kinase Inhibitor
11%
Mammalian Target of Rapamycin
11%
Gene Dosage
11%
Extracellular Matrix Protein
11%
Diseases
11%
Pharmacology, Toxicology and Pharmaceutical Science
Phosphatidylinositol 3 Kinase
100%
Pancreas Cancer
100%
Pancreas Adenocarcinoma
100%
Mammalian Target of Rapamycin Inhibitor
100%
Dactolisib
55%
Clinical Trial
22%
Murine
11%
Malignant Neoplasm
11%
Matrix Protein
11%
Tumor Model
11%
Cyclin Dependent Kinase Inhibitor
11%
Phosphatidylinositol 3 Kinase Inhibitor
11%
Diseases
11%
Immunology and Microbiology
Cancer Cell
100%
Adenocarcinoma Cell Line
100%
Matrix Protein
50%
Cycline
50%
Murine
50%
Haploinsufficiency
50%
Gene Dosage
50%
Extracellular Matrix
50%
Biochemistry, Genetics and Molecular Biology
Mammalian Target of Rapamycin
100%
Cancer Cell
100%
Phosphoinositide 3-Kinase
100%
Clinical Trial
40%
Gene Dosage
20%
Murine
20%
Haploinsufficiency
20%
Extracellular Matrix Protein
20%
Cyclin-Dependent Kinase
20%
Phosphoinositide 3-Kinase Inhibitor
20%
Targeted Therapy
20%